Overview of proposal from UK, and group discussion/feedback.

Link to discussion & proposal paper: Unit of Measure - rationalisation of concepts

1. Yong has added a comment to the discussion board:
https://confluence.ihtsdotools.org/display/USRG/Additional+Attributes+for+National+Drug+Extensions
This includes a proposed new MRCM for 30465011000036106 |Has container type (attribute)|. Yong has raised questions regarding the domain, range (especially with respect to specific physical object values), and cardinality (also consider multi-container products, subpacks, and the implications for classification).

2. The attributes list from Canada is also available on the discussion board. Additional relevant content can be found on this page:
https://confluence.ihtsdotools.org/display/USRG/Medication+MRCM+Extensions

What are members requirements in the area of additional attributes?

Work ongoing

Request for feedback on Patches strength representation

Group feedback on applying ongoing patch strength changes to Vaginal Rings

Consolidation of Medicinal Product Model into the Editorial Guide.

• Less Granular Clinical Drug
• Elemental Substances (Matt, AUS)
• Substances Co-ordination (MF/2025 Priority topic)
  • Step 1: Substances in multiple extensions Batch promotions complete, SI review and authoring underway
  • Step 2: Substances in one extension
  • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)
• Medication Stopped v Medication Discontinued (Karen, SI)
• Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)
• Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 
• Increase range of has active ingredient to include microorganisms and natural products (Guillermo)
• Link between Substances and the organism they come from (Cat dander protein → Cat organism) see PCP-68
• Units of Measure - proposal for rationalisation of concepts (Emma, UK)

Done or in progress:

• Hydration Subsumption 'Option 3' proposed by DEUSG for communication/consultation with MAG and EAG
• Group Input on Patch Strength Representation Briefing note now being implemented
• Dose Form Intended Site v Route of Administration (BEL) Pending implementation use-cases associated with intended site
• Drug extension MRCM attributes (CA, AUS) SI facilitating links with CA and AUS for cross-promotion, next steps: other countries to be invited to add to catalogue
• Value range of a |Has container type| attribute (Linda, CA)
• Routes of Administration - Implementation Considerations (Mia, NZ)